Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice

Qian Ye, Yi Liu, Guiji Zhang, Haijun Deng, Xiaojun Wang, Lin Tuo, Chang Chen, Xuanming Pan, Kang Wu, Jiangao Fan, Qin Pan, Kai Wang (), Ailong Huang () and Ni Tang ()
Additional contact information
Qian Ye: Chongqing Medical University
Yi Liu: Chongqing Medical University
Guiji Zhang: Chongqing Medical University
Haijun Deng: Chongqing Medical University
Xiaojun Wang: Third Military Medical University (Army Medical University)
Lin Tuo: Hospital of the University of Electronic Science and Technology of China and Sichuan Provincial People’s Hospital
Chang Chen: Chongqing Medical University
Xuanming Pan: Chongqing Medical University
Kang Wu: Chongqing Medical University
Jiangao Fan: Shanghai Jiao Tong University
Qin Pan: Shanghai Jiao Tong University
Kai Wang: Chongqing Medical University
Ailong Huang: Chongqing Medical University
Ni Tang: Chongqing Medical University

Nature Communications, 2023, vol. 14, issue 1, 1-19

Abstract: Abstract Metabolic associated fatty liver disease (MAFLD) encompasses a broad spectrum of hepatic disorders, including steatosis, nonalcoholic steatohepatitis (NASH) and fibrosis. We demonstrated that phosphoenolpyruvate carboxykinase 1 (PCK1) plays a central role in MAFLD progression. Male mice with liver Pck1 deficiency fed a normal diet displayed hepatic lipid disorder and liver injury, whereas fibrosis and inflammation were aggravated in mice fed a high-fat diet with drinking water containing fructose and glucose (HFCD-HF/G). Forced expression of hepatic PCK1 by adeno-associated virus ameliorated MAFLD in male mice. PCK1 deficiency stimulated lipogenic gene expression and lipid synthesis. Moreover, loss of hepatic PCK1 activated the RhoA/PI3K/AKT pathway by increasing intracellular GTP levels, increasing secretion of platelet-derived growth factor-AA (PDGF-AA), and promoting hepatic stellate cell activation. Treatment with RhoA and AKT inhibitors or gene silencing of RhoA or AKT1 alleviated MAFLD progression in vivo. Hepatic PCK1 deficiency may be important in hepatic steatosis and fibrosis development through paracrine secretion of PDGF-AA in male mice, highlighting a potential therapeutic strategy for MAFLD.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-37142-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37142-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-37142-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().